- Veeva Systems Expands AI and Vault CRM Momentum: Time to Buy or Hold?
May 14, 2026
Veeva Systems VEEV has shown strong momentum during fiscal 2026 across its commercial and R&D businesses, supported by rising Vault CRM adoption, expanding AI initiatives and deeper enterprise partnerships across the life sciences industry. The company’s customers are actively migrating toward Vault CRM and demand for its AI-enabled workflow automation across commercial, safety and clinical operations continue to grow. VEEV is also expanding its strategic relationships with major biopharma companies, while also strengthening its AI capabilities through acquisition.
The pharmaceutical companies are increasingly prioritizing modern core systems, workflow automation and AI-ready infrastructure rather than relying on fragmented legacy environments. The company noted rising customer interest in AI-powered content generation, compliant commercial workflows, safety automation and connected clinical ecosystems, supported by Veeva’s growing portfolio of AI agents and integrated cloud applications. However, management acknowledged that AI adoption across life sciences remains in the early stages, with most customers still focused on experimentation, workflow optimization and gradual deployment of agentic AI capabilities rather than broad enterprise-scale monetization.
Competition within the life sciences software and AI ecosystem continues to intensify as peers expand their healthcare AI, data analytics and workflow automation capabilities. IQVIA IQV continues strengthening its AI and clinical research positioning through the launch of IQVIA.ai alongside NVIDIA, expansion of its drug discovery offerings and deeper collaborations across clinical development and healthcare analytics.
Meanwhile, Salesforce CRM is aggressively expanding its enterprise healthcare AI footprint through Agentforce, strategic partnerships with OpenAI and Anthropic and broader deployment of generative AI agents across healthcare and regulated-industry workflows. Additionally, Oracle ORCL continues expanding its healthcare and life sciences presence following the Cerner acquisition, while increasing investments in AI-driven clinical workflows, cloud infrastructure and healthcare data management solutions targeted at regulated industries.
VEEV Stock’s Price Performance
In the year-to-date period, Veeva Systems shares have plunged 30.2%, underperforming the broader Zacks Medical Information Systems industry’s decline of 22.9%. Among peers, Oracle has emerged as the strongest performer, dipping only 2.6% during the period, while IQVIA shares have lost 23.5%. Meanwhile, Salesforce has been the weakest performer among the group, plummeting 37.2% year to date.
Story Continues
The sharp decline in VEEV shares reflects broader pressure across healthcare IT and enterprise software stocks despite the company’s solid AI, Vault CRM and commercial cloud momentum.Zacks Investment Research
Image Source: Zacks Investment Research
Why VEEV Remains a Hold for Now
Expanding Vault CRM Adoption Supports Commercial Momentum: Veeva Systems continues to benefit from rising Vault CRM adoption as pharmaceutical companies transition away from legacy CRM environments toward AI-enabled commercial platforms. Management noted that nearly 140 customers are now live on Vault CRM, including multiple top-20 pharmaceutical companies, while additional migrations remain underway globally.
The company is also seeing customers adopt products such as Network, OpenData, Service Center and Campaign Manager alongside Vault CRM deployments, expanding cross-sell opportunities across Commercial Cloud. Growing demand for compliant AI-powered content generation, omnichannel engagement and workflow automation further supports Veeva Systems’ commercial momentum.
AI Partnerships and Ostro Acquisition Strengthen Competitive Positioning: Veeva continues accelerating its AI strategy through expanding partnerships and product innovation across commercial and R&D workflows. During the quarter, the company expanded strategic relationships with BioMarin and Roche, with Roche selecting Vault CRM globally alongside plans to deploy Veeva AI Agents for CRM automation workflows. Veeva also strengthened its AI capabilities through the acquisition of Ostro, an AI-powered engagement platform designed specifically for life sciences companies. Management expects tighter integration between Ostro and Veeva’s Commercial Cloud applications over time, enabling more personalized and automated physician and patient engagement workflows.
Expanding R&D and Safety Momentum Supports Long-Term Growth: Veeva Systems continues gaining traction across its R&D business as pharmaceutical companies modernize core clinical, safety and data management systems. Management highlighted growing adoption of newer products such as RTSM, EDC, Safety and LIMS, alongside additional top-20 customer wins in safety and RTSM during the quarter.
The company also sees increasing opportunities within study-by-study clinical deployments through CRO partnerships, particularly across EDC, RTSM and eCOA offerings. While AI monetization remains in the early stages, expanding enterprise adoption, deeper platform integration and rising demand for AI-enabled workflow automation continue to support Veeva Systems’ long-term growth outlook.
VEEV’s Sales & EPS Growth
In fiscal 2027, VEEV is expected to deliver a 12.5% improvement in revenues. On the profitability front, earnings per share are expected to increase 8.8% year over year.Zacks Investment Research
Image Source: Zacks Investment Research
VEEV’s Key Challenge
AI Monetization and CRM Transition Risks Remain Key Overhangs: Veeva Systems continues to face challenges around the pace of AI monetization and the complexity of large-scale CRM migrations despite growing customer interest in AI-enabled workflows. Management acknowledged that most pharmaceutical customers remain in the early stages of experimenting with AI agents, workflow automation and compliant content generation rather than deploying enterprise-wide production-scale AI applications.
At the same time, Veeva Systems remains heavily dependent on the successful execution of ongoing Vault CRM migration projects, particularly among large pharmaceutical companies transitioning away from legacy Salesforce-based environments. The company also noted that some customers continue pursuing custom-built CRM initiatives with systems integrators, which could create competitive pressures and delay broader adoption cycles. While Veeva Systems expects AI and Vault CRM to remain major long-term growth drivers, the pace of enterprise deployment, customer readiness and execution risks surrounding large transformation projects remain key overhangs on the stock.
VEEV Stock’s Valuation Picture
VEEV stock seems to be trading at a decent valuation, as suggested by the Value Score of C.
VEEV is currently trading at a price-to-book (P/B) ratio of 3.53X, which is lower than the industry average of 6.09X.Zacks Investment Research
Image Source: Zacks Investment Research
How to Approach VEEV Stock
Veeva Systems continues to strengthen its position in life sciences software through expanding Vault CRM adoption, growing AI capabilities and deeper enterprise partnerships across commercial and R&D workflows. The company is benefiting from rising demand for AI-enabled workflow automation, compliant content generation and modernized cloud platforms as pharmaceutical companies move away from legacy systems. Strategic partnerships with BioMarin and Roche, alongside the acquisition of Ostro, further reinforce Veeva Systems’ long-term AI and commercial cloud growth opportunities.
However, AI monetization across the life sciences industry remains in the early stages, with most customers still focused on experimentation and gradual deployment of agentic AI applications rather than large-scale production adoption. Veeva Systems also faces execution risks tied to ongoing Vault CRM migration projects and increasing competition from enterprise AI and healthcare technology providers. With a Zacks Rank #3 (Hold), the stock appears appropriately valued at current levels while investors await broader AI commercialization and sustained long-term growth acceleration. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Salesforce, Inc. (CRM) : Free Stock Analysis Report
Oracle Corporation (ORCL) : Free Stock Analysis Report
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
IQVIA Holdings Inc. (IQV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Veeva Systems Expands AI and Vault CRM Momentum: Time to Buy or Hold?
May 14, 2026 · zacks.com
VEEV expands Vault CRM adoption and AI capabilities with Roche and BioMarin partnerships as life sciences firms modernize workflows.
- Veeva Commercial Summit to Feature Biopharma's AI Successes and the Path to Agentic Commercial
May 14, 2026
argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk, Takeda, and Vertex share how they are redefining engagement across sales, marketing, and medical
PLEASANTON, Calif., May 14, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will showcase the future of agentic commercial in biopharma at Veeva Commercial Summit, May 19-20 in Boston. Leaders from argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk, Takeda, Vertex, and more will share AI successes and explore new approaches to commercial engagement.Veeva Systems (PRNewsfoto/Veeva Systems)
Veeva will highlight its vision for Agentic Commercial, bringing together industry-specific AI, data, and applications to help the industry advance and deliver better medicine to more patients. Organizations ranging from top 20 biopharmas to emerging biotechs will share how they are leveraging new strategies, technologies, and insights to improve engagement and deliver measurable value.
More than 100 sessions at Summit will highlight what's new in Commercial Cloud and Data Cloud, and customer successes, including:
Accelerating Agentic Commercial at scale
Genentech, Gilead, and Novo Nordisk advancing innovation with next-generation CRM GSK's vision for shaping customer engagement with Vault CRM and Veeva AI Avidity Biosciences, A Novartis Company, and Boehringer Ingelheim's agentic content strategy for faster quality reviews Boehringer Ingelheim and Gilead giving doctors and patients instant, compliant answers
Precision data powering AI, faster insights, actions, and launch success
Merck and Takeda integrating deep data to drive business processes and AI MoonLake and Unicycive using modern data to quickly identify and engage patients argenx's media measurement framework for its DTC launch strategy
Medical driving impact and improved patient outcomes
GSK and Vertex establishing a modern operating system for medical affairs Astellas, Bayer, and Chiesi USA capturing and sharing medical insights to drive action
With more than 2,000 industry professionals, Veeva Commercial Summit is the largest commercial and medical event in North America. More than 40 sponsoring partners include Accenture, Conexus, Cognizant, EY, IQVIA, and Slipstream. The event is open exclusively to life sciences professionals who can register at veeva.com/Summit.
About Veeva Systems Veeva delivers the industry cloud for life sciences with software, AI, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Story Continues
Veeva Forward-Looking Statements This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 13 and 14), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Maria Scurry
Veeva Systems
maria.scurry@veeva.comCision
View original content to download multimedia:https://www.prnewswire.com/news-releases/veeva-commercial-summit-to-feature-biopharmas-ai-successes-and-the-path-to-agentic-commercial-302771854.html
View Comments
- Veeva Commercial Summit to Feature Biopharma's AI Successes and the Path to Agentic Commercial
May 14, 2026 · prnewswire.com
argenx, Bayer, Boehringer Ingelheim, Genentech, Gilead, GSK, Merck, Novo Nordisk, Takeda, and Vertex share how they are redefining engagement across sales, marketing, and medical PLEASANTON, Calif., May 14, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will showcase the future of agentic commercial in biopharma at Veeva Commercial Summit, May 19-20 in Boston.
- VEEVA COMMERCIAL SUMMIT TO FEATURE BIOPHARMA'S AI SUCCESSES AND THE PATH TO AGENTIC COMMERCIAL
May 14, 2026
ARGENX, BAYER, BOEHRINGER INGELHEIM, GENENTECH, GILEAD, GSK, MERCK, NOVO NORDISK, TAKEDA, AND VERTEX SHARE HOW THEY ARE REDEFINING ENGAGEMENT ACROSS SALES, MARKETING, AND MEDICAL PLEASANTON, CALIF., MAY 14, 2026 /PRNEWSWIRE/ -- VEEVA SYSTEMS (NYSE: VEEV) WILL SHOWCASE THE FUTURE OF AGENTIC COMMERCIAL IN BIOPHARMA AT VEEVA COMMERCIAL SUMMIT, MAY 19-20 IN BOSTON.
- Veeva Systems (VEEV) Stock Falls Amid Market Uptick: What Investors Need to Know
May 13, 2026
In the latest close session, Veeva Systems (VEEV) was down 1.94% at $156.33. The stock's performance was behind the S&P 500's daily gain of 0.59%. Meanwhile, the Dow experienced a drop of 0.14%, and the technology-dominated Nasdaq saw an increase of 1.2%.
Heading into today, shares of the provider of cloud-based software services for the life sciences industry had gained 0.21% over the past month, outpacing the Medical sector's loss of 0.02% and lagging the S&P 500's gain of 8.64%.
Analysts and investors alike will be keeping a close eye on the performance of Veeva Systems in its upcoming earnings disclosure. On that day, Veeva Systems is projected to report earnings of $2.13 per share, which would represent year-over-year growth of 8.12%. Alongside, our most recent consensus estimate is anticipating revenue of $857.33 million, indicating a 12.95% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.81 per share and a revenue of $3.59 billion, signifying shifts of +8.77% and +12.47%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Veeva Systems. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. At present, Veeva Systems boasts a Zacks Rank of #3 (Hold).
Looking at valuation, Veeva Systems is presently trading at a Forward P/E ratio of 18.09. This expresses a discount compared to the average Forward P/E of 25.55 of its industry.
One should further note that VEEV currently holds a PEG ratio of 0.52. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical Info Systems industry was having an average PEG ratio of 1.45.
Story Continues
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 100, finds itself in the top 41% echelons of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Doximity (DOCS) Lags Q4 Earnings Estimates
May 13, 2026
Doximity (DOCS) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -7.14%. A quarter ago, it was expected that this medical social networking site would post earnings of $0.44 per share when it actually produced earnings of $0.46, delivering a surprise of +4.55%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Doximity, which belongs to the Zacks Medical Info Systems industry, posted revenues of $145.37 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.19%. This compares to year-ago revenues of $138.29 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Doximity shares have lost about 40.3% since the beginning of the year versus the S&P 500's gain of 8.1%.
What's Next for Doximity?
While Doximity has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Doximity was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.34 on $153 million in revenues for the coming quarter and $1.59 on $690.29 million in revenues for the current fiscal year.
Story Continues
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Veeva Systems (VEEV), another stock in the same industry, has yet to report results for the quarter ended April 2026.
This provider of cloud-based software services for the life sciences industry is expected to post quarterly earnings of $2.13 per share in its upcoming report, which represents a year-over-year change of +8.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Veeva Systems' revenues are expected to be $857.33 million, up 13% from the year-ago quarter.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Doximity, Inc. (DOCS) : Free Stock Analysis Report
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Veeva to Release Fiscal 2027 First Quarter Results on June 3, 2026
May 13, 2026
PLEASANTON, Calif., May 13, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its first quarter ending April 30, 2026 after market close on June 3, 2026. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results.
Veeva will post prepared remarks to its investor relations website at ir.veeva.com at approximately 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website following the live event.
Event: Veeva Systems' Fiscal 2027 First Quarter Results Conference Call Date: Wednesday, June 3, 2026 Time: 2:00 p.m. PT (5:00 p.m. ET) Conference Call Registration: https://events.q4inc.com/analyst/423437130?pwd=ckfYa8Xa Webcast: ir.veeva.com
About Veeva Systems Veeva delivers the industry cloud for life sciences with software, AI, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.
Investor Relations Contact: Gunnar Hansen
Veeva Systems Inc.
267-460-5839
ir@veeva.com
Media Contact: Maria Scurry
Veeva Systems Inc.
781-366-7617
pr@veeva.comCision
View original content:https://www.prnewswire.com/news-releases/veeva-to-release-fiscal-2027-first-quarter-results-on-june-3-2026-302771259.html
View Comments
- Veeva Systems (VEEV) Stock Falls Amid Market Uptick: What Investors Need to Know
May 13, 2026 · zacks.com
Veeva Systems (VEEV) closed the most recent trading day at $156.33, moving 1.94% from the previous trading session.
- VEEV Boosts MedTech Quality Management With Smith+Nephew Partnership
May 13, 2026
Veeva Systems VEEV recently announced the adoption of Veeva Quality Cloud by Smith+Nephew or Smith & Nephew SNATS SNN to unify and modernize its global quality management operations. The implementation includes Veeva QualityDocs, Veeva QMS and Veeva Training, establishing a centralized quality foundation to support the company’s quality transformation strategy.
VEEV will provide Smith & Nephew with Veeva QualityDocs to serve as a centralized platform for managing controlled quality content, while Veeva QMS will standardize processes, align global operations and enhance collaboration. Additionally, Veeva Training will streamline access to more than 500,000 annual training activities, supporting job and audit readiness.
Management stated that the company is proud to support Smith & Nephew to enhance operational efficiency and expand patient reach through the scalable, end-to-end capabilities of Veeva Quality Cloud. Modernizing quality management processes can support the company’s future growth and innovation initiatives.
Likely Trend of VEEV Stock Following the News
Shares of VEEV have gained 0.1% since the announcement on Monday. In the year-to-date period, shares of the company lost 28.6% compared with the industry’s 22.1% decline. However, the S&P 500 has risen 8.9% in the same timeframe.
The adoption of Veeva Quality Cloud by Smith & Nephew is expected to strengthen Veeva Systems’ position in the growing medtech quality management market. The partnership highlights increasing industry demand for cloud-based quality and compliance solutions that improve operational efficiency and regulatory readiness. Expanding adoption among large global medtech companies, including BioMarin and Roche, could support VEEV’s long-term recurring revenue growth and reinforce its competitive position in enterprise quality management software.
VEEV currently has a market capitalization of $26.02 billion.Zacks Investment Research
Image Source: Zacks Investment Research
More on Veeva Quality Cloud
A major advantage of Veeva Quality Cloud is its ability to eliminate disconnected systems and bring quality processes into a single ecosystem. Veeva QualityDocs provides a centralized system for managing quality, manufacturing, validation and other GxP documents. The platform streamlines document authoring, reviewing, approval and control processes, helping organizations maintain compliance efficiently.
Veeva QMS standardizes global quality workflows, including audits, CAPAs, complaints, supplier management, field actions and change controls. The unified system improves process visibility and supports proactive quality risk management across organizations.
Story Continues
Veeva Training further strengthens compliance by centralizing training records and automating qualification management. Integrated with Veeva QMS and QualityDocs, the solution simplifies training distribution, improves audit readiness and ensures employees remain compliant with evolving regulatory standards.
Industry Prospects Favoring the Market
Going by the data provided by Market Research Future, the healthcare quality management market was valued at $923.5 million in 2025 and is projected to reach $3.22 billion by 2035, expanding at a CAGR of 13.3% from 2025 to 2030.
Factors like the emphasis on value-based care, integration of data analytics, increased focus on patient safety, growing importance of accreditation and rising demand for quality improvement are boosting the market’s growth.
Other News
In March, Veeva Systems acquired Ostro, an artificial intelligence (AI)-powered brand engagement platform designed for the life sciences industry. The platform enables pharmaceutical companies to provide patients and healthcare professionals with real-time, compliant answers through conversational AI on brand websites.
Veeva Systems Inc. PriceVeeva Systems Inc. Price
Veeva Systems Inc. price | Veeva Systems Inc. Quote
VEEV’s Zacks Rank & Key Picks
Currently, VEEV has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical WST and Globus Medical GMED.
West Pharmaceutical, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Smith & Nephew SNATS, Inc. (SNN) : Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
Globus Medical, Inc. (GMED) : Free Stock Analysis Report
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
